1Hodel Christian. Myopathy and rhabdomyolysis with lipidlowering drugs.Toxicol - Lett,2002,128( 1 - 3) : 159 - 168.
2Endo A, Kurado M, Tanazawa K. Citrinin, an inhibitor of cholesterol synthesis. FEBS Lett , 1976,29: 841.
3Steiner S, Gatlin CL, Lennon J J, et al. Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin.Toxicol Lett ,2001,120(1 - 3) :369.
4Pedersen TR, Wilhelmsen L, Faergeman O, et al.Follow- up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol, 2000,86(3):257.
5Hilleman DE, Wurdeman RL, Lenz TL. Therapeutic change of HMG - CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy ,2001,21( 4 ) :410.
6Hussein O, Schlezinger S, Rosenblat M, et al.Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy of the drug and its binding to the LDL.Atherosclerosis , 1997,128:11.
7Girona J, Ville AE, Sola R, et al. Simvastatin de creases aldehyde production derived from lipoprotein oxidation. Am J Cardiol, 1999, 83: 846.
8Williams JK, Sukhova G, Herrington DM, et al.Pravastains has cholesterol lowering independent effect on the artery wall of atheroslerotic monkeys. J Am Coll Cadiol, 1998,31:684.
9Sakai M, Kobori S, Matsumura J, et al. HMGCOA reducted inhibitors surpress macrophage growth induced by oxidized low density lipoprotein.Atherosclerosis, 1997, 133:51.
10Katznelson S. The inhibitory of effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant, 1998,17(40) ;335.
